Taigen Biotechnology Co. Ltd., of Taipei, Taiwan, said the FDA granted Taigexyn (nemonoxacin) qualified infectious disease product and fast track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Read More

SHANGHAI – Simcere Pharmaceutical Group has completed a management buyout first announced in March and subsequent delisting from the New York Stock Exchange (NYSE:SCR). Going private will protect the company from revealing information publicly during a sensitive time as Chinese biopharmas have been rocked by bribery scandals for the past six months. Read More

HONG KONG – Looking to expand its range of biotech products, a state-owned Chinese trading conglomerate will work with Cuba’s largest biotechnology firm to expand its product offerings while helping its smaller partner expand its global presence. Read More

SHANGHAI – In 2011 Shanghai-based Hua Medicine Ltd. made headlines in China as a start-up R&D biotech flush with a $50 million commitment from venture capital investors and a crew of talented veterans as founders and board members. Read More

Multinational biopharmaceutical companies will see the door to China swing open wider this year if the country’s new leadership delivers on promises made in November to let market forces dominate. Read More